Strong Scientific Leadership
Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (UH CINEMA) includes some of the world’s foremost experts in the clinical care of patients with diabetes who also have cardiovascular complications, prevention and therapy of cardiometabolic disease, translational research, and implementation science.
Personalized Approaches for Management of Type 2 Diabetes
Identifying the patient with type 2 diabetes at risk for future cardiovascular and metabolic complications is a vital important goal. UH CINEMA is at the national forefront of leading-edge technologies to help resolve individual risk in patients with type 2 diabetes – to determine whether they are at risk and utilize these approaches in risk stratification and treatment.
Clinical Trials and Implementation Science
There are currently more than ten clinical trials at UH Cleveland Medical Center that directly address patients with type 2 diabetes and involve novel devices for percutaneous intervention, wound care, and drug approaches. In addition, multiple trials are targeting metabolic complications of type 2 diabetes throughout the University Hospitals system, such as:
The BODY-REAL Study
Clinical effectiveness of body fat distribution imaging in real-world practice
Continuous Glucose Monitoring Device Study
Patient Registry Sub-Study Consent: Feasibility and Clinical Utility of the Dexcom in CINEMA Program Patients
Translational Science Unit (TSU)
This Translational Science Unit interfaces with all clinical and basic science programs, allowing unique opportunities to cross-fertilize and address fundamental questions in metabolic disorders, including early diagnosis and treatment of vascular diseases with real-time intervention. The TSU also provides the necessary infrastructure for investigator-initiated studies.
Lessons Learned From a Patient‐Centered, Team‐Based Intervention for Patients With Type 2 Diabetes at High Cardiovascular Risk: Year 1 Results From the CINEMA Program
The care for patients with type 2 diabetes necessitates a multidisciplinary team approach to reduce cardiovascular risk, but implementation of effective integrated strategies has been limited.